Syneos Health Signs Agreement with University of the Sunshine Coast to Support Clinical Trials in Australia
February 21, 2024
MORRISVILLE, N.C. – February 21, 2024 – Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, has signed an agreement with the University of the Sunshine Coast. The agreement further expands the Company’s clinical trial capabilities across a broader range of therapeutic areas in Australia.
The University of the Sunshine Coast now becomes part of the Syneos Health Catalyst and Site Network Partnerships program, including 110+ clinical sites and 60+ commercial site networks. As part of the Site Network Partnerships program, the University of the Sunshine Coast joins a select set of high-performing investigative site networks strategically aligned to Syneos Health’s clinical studies. Site Network Partnerships provide enhanced patient access, improved efficiencies, specialized expertise and access to diverse patient populations across all therapeutic areas and phases.
“We are thrilled to partner with the University of the Sunshine Coast. This venture cements our desire to form a longstanding and productive partnership to shorten the distance from lab to life and improve access to clinical trials in the Australian market,” said David Gebbo, Director and Transformation and Delivery Lead for Clinical Operations, APAC, Syneos Health. “This collaboration supports our strong focus in achieving consistent quality and streamlined delivery on clinical trials to accelerate the development of therapies for patients.”
The University of the Sunshine Coast consists of a network of sites across Queensland and is committed to delivering clinical trials of genuine value in areas of the community otherwise largely unrepresented.
“This is an exciting step forward for our organization as we join the Syneos Health Catalyst and Site Network Partnerships program. Our expanding network continues to deliver early phase healthy volunteer phase 1 studies, and chronic disease, vaccine and cancer trials in partnership with industry and community,” said Lucas Litewka, Director, University of the Sunshine Coast Clinical Trials.
About Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.
Syneos Health Press/Media Contact:
Meg Byers
Associate Director, External Communications
+1 607 215 1330
